Description
Bronchogen is a synthetic tetrapeptide (Ala-Glu-Asp-Leu) of the Khavinson bioregulator class. The substance was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson, with the research goal of lung- and bronchi-specific gene expression modulation.
Per study reports Bronchogen is described as acting via an epigenetic mechanism: short peptides bind to specific DNA regulator regions and modulate gene activity in target tissue without changing the DNA sequence itself. In Bronchogen’s case the action should primarily occur in broncho-pulmonary tissue - protein synthesis stimulation in bronchi, reduction of age-related peptide deficits, normalization of bronchial cell function.
The data base spans over 40 years of Russian research but is little replicated internationally. Most studies come from the Khavinson institute itself. Multi-year human studies on hundreds of participants are reported in Russian literature; peer-reviewed replication from Western Europe or the USA remains limited.
The substance is typically used in 10-20 day courses two or three times per year. Per course typically 1-2 vials, the Khavinson standard scheme. Subcutaneous or intramuscular injection is the typical administration form.
Bronchogen has a very low side effect profile in available literature. With subcutaneous use, mild injection-site reactions are possible.
You can order Bronchogen as lyophilized peptide in 10-pack at 20mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Bronchogen is classified as remarkably mild in the available literature and is among the most well tolerated compounds in the research range. Across more than 40 years of Russian bioregulator research, no relevant toxic effects have been documented.
Observed in research and reports:
- Injection site: mild redness or transient irritation with subcutaneous use is the most common observation. The tetrapeptide itself is considered low-reactivity.
- Very thin human data: the data base consists almost entirely of small, Russian-language studies from the Khavinson institute. Peer-reviewed replication from Western Europe or the USA is largely absent. Robust long-term safety data do not exist.
- Course-based pattern: the use described in the literature occurs in short 10-20 day courses, not as continuous use. No data exist on the safety profile of continuous administration.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium - Lung 2014, Khavinson et al: mechanism paper on the action of short peptides in bronchial epithelium.
- Effect of the Peptide Bronchogen (Ala-Asp-Glu-Leu) on DNA Thermostability - Bulletin of Experimental Biology and Medicine 2011, Monaselidze et al: biophysical study of AEDL-DNA interaction.
- Peptide Regulation of Gene Expression: A Systematic Review - Molecules 2021, Khavinson et al: review of the bioregulator class and gene expression effects across the Khavinson peptide group.
- Peptide bioregulation of aging: results and prospects - Biogerontology 2010, Anisimov and Khavinson: aging mechanism review of the bioregulator class.
